6AA-28029-19432
4 vaccinations
3 coded responses
33 check-ins
3 free-text entries
2 call cases
- Sex
- Female
- Age at first dose
- 61-65
- ZIP prefix
- 337 / FL
- Registered
- 2021-01-22
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-22
Registered in v-safe
-
2021-01-22
Dose 1 — Pfizer-BioNTech
- 2021-01-22
-
2021-01-23
Health check-in — days 1–6 daily, dose 1Feeling: Fair · Fever · Headache, Fatigue or tirednessAdult check-in
- 2021-01-24
- 2021-01-25
-
2021-01-26
Health check-in — days 1–6 daily, dose 1Feeling: Fair · Fever · Headache, Fatigue or tirednessAdult check-in
- 2021-01-27
- 2021-01-28
- 2021-01-29
- 2021-02-05
-
2021-02-12
Dose 2 — Pfizer-BioNTech
- 2021-02-12
-
2021-02-13
Survey response — days 1–6 daily, dose 2MedDRA: Condition aggravated, Migraine, Pre-existing disease — Feeling: Fair · Site: Pain · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesFree text: Exacerbation of trigeminal neuralgia & migraineMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-02-14
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Headache, Joint pains, Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesAdult check-in
-
2021-02-15
Health check-in — days 1–6 daily, dose 2Feeling: Good · Headache, Muscle or body aches, Fatigue or tirednessAdult check-in
-
2021-02-16
Health check-in — days 1–6 daily, dose 2Feeling: Good · Headache, Fatigue or tirednessAdult check-in
- 2021-02-17
- 2021-02-18
- 2021-02-19
- 2021-02-26
- 2021-03-05
- 2021-03-12
- 2021-03-19
- 2021-03-26
- 2021-05-14
- 2021-08-13
-
2021-09-01
Dose 3 — Pfizer-BioNTech
- 2021-10-01
- 2021-10-06
- 2021-10-14
- 2021-12-01
-
2022-03-02
Survey response — 6 months, dose 3MedDRA: Brain fog, Cough, Dyspnoea exertional, Fatigue, Myalgia, Office visit, Oxygen saturation decreased, Telemedicine — Feeling: Fair · Be unable to do your normal daily activities, Get care from a doctor or other healthcare professionalFree text: Symptoms: Severe exhaustion with minor activity/ dyspnea with moderate exertion/ muscle aches/ pulse ox drops from 98- 99% at rest to 93-96% with activity- brain fog minor-persistent nearly nonstop nonproductive cough that lasted 54+ days finally is subsiding. · Healthcare visit (other): Pcp telehealth and a follow up in person visitMedDRA releases: 2024-11 · check-in free text available
-
2022-03-02
Report sent to call center — 6 months, dose 3Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional1 call case(s)
- 2022-03-03
-
2022-04-08
Dose 4 — Pfizer-BioNTech
- 2022-05-18
- 2022-05-20
-
2022-07-11
Survey response — 3 months, dose 4MedDRA: Dyspnoea exertional, Fatigue, Parosmia — Feeling: Fair · Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: Increased dyspnea with less exertion. No resolution of easily fatigue. My sense of smell is off and worse than beforeMedDRA releases: 2024-11 · check-in free text available
-
2022-07-11
Report sent to call center — 3 months, dose 4Get care from a doctor or other healthcare professionalTelehealth, virtual health, or email health consultation · 1 call case(s)
- 2022-07-12
- 2022-10-09
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-22 | Pfizer-BioNTech | |
| 2 | 2021-02-12 | Pfizer-BioNTech | |
| 3 | 2021-09-01 | Pfizer-BioNTech | No |
| 4 | 2022-04-08 | Pfizer-BioNTech | No |
Call center
2 call center cases
2 unsuccessful
Free text
Release 4 — days 1–6 daily, dose 2
Systemic reaction (other): Exacerbation of trigeminal neuralgia & migraine
Release 11 — 6 months, dose 3
Symptoms: Severe exhaustion with minor activity/ dyspnea with moderate exertion/ muscle aches/ pulse ox drops from 98- 99% at rest to 93-96% with activity- brain fog minor-persistent nearly nonstop nonproductive cough that lasted 54+ days finally is subsiding. cut off by CDC
Healthcare visit (other): Pcp telehealth and a follow up in person visit
Release 12 — 3 months, dose 4
Symptoms: Increased dyspnea with less exertion. No resolution of easily fatigue. My sense of smell is off and worse than before
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| HCVO | Office visit | · | · | ✓ |
| HCVO | Telemedicine | · | · | ✓ |
| SD | Brain fog | · | · | ✓ |
| SD | Cough | · | · | ✓ |
| SD | Dyspnoea exertional | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Myalgia | · | · | ✓ |
| SD | Oxygen saturation decreased | · | · | ✓ |
| SD | Parosmia | · | · | ✓ |
| SRO | Condition aggravated | ✓ | ✓ | ✓ |
| SRO | Migraine | ✓ | ✓ | ✓ |
| SRO | Pre-existing disease | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release